PA
CRVS icon

Parallel Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Parallel Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20
Closed -$106 – 3538
2024
Q3 		$106 Hold
20
– – ﹤0.01% 3334
2024
Q2 		$36 Hold
20
– – ﹤0.01% 3278
2024
Q1 		$36 Hold
20
– – ﹤0.01% 3239
2023
Q4 		$35 Hold
20
– – ﹤0.01% 3265
2023
Q3 		$29 Hold
20
– – ﹤0.01% 3317
2023
Q2 		$46 Hold
20
– – ﹤0.01% 3314
2023
Q1 		$18 Hold
20
– – ﹤0.01% 3392
2022
Q4 		$17 Hold
20
– – ﹤0.01% 3320
2022
Q3 		$0 Hold
20
– – ﹤0.01% 3200
2022
Q2 		$0 Hold
20
– – ﹤0.01% 3054
2022
Q1 		$0 Hold
20
– – ﹤0.01% 3020
2021
Q4 		$0 Hold
20
– – ﹤0.01% 3120
2021
Q3 		$0 Hold
20
– – ﹤0.01% 3101
2021
Q2 		$0 Buy
+20
New +$55 ﹤0.01% 2956

Other funds holding CRVS

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
SC
Samlyn Capital New York $5.82B AUM 36.3% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $77.3B AUM 36.07% 1-Year Est. Return